Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a retrospective study in Mexican population

Maintenance therapy with fluoropyrimidines demonstrates a favorable survival benefit and manageable toxicity profile in advanced esophago-gastric adenocarcinoma. Despite limitations, including the study's retrospective design and the absence of direct comparisons with non-maintenance groups, these findings align with international studies, suggesting that fluoropyrimidines offer an effective strategy to prolong the benefits of first-line treatment in gastric cancer. Further studies incorporating human epidermal growth factor receptor 2 (HER2) and immune checkpoint inhibitors are warranted to enhance therapeutic personalization.